Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Linac FRACtionated Radiosurgical THALamotomie in Tremors (FRACTHAL) (FRACTHAL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04727658
Recruitment Status : Not yet recruiting
First Posted : January 27, 2021
Last Update Posted : January 27, 2021
Information provided by (Responsible Party):
Centre Hospitalier Universitaire de Nice

Brief Summary:

Radiosurgical thalamotomy on GammaKnife has been shown to be effective in the management of tremors. However, several teams describe a significant risk of severe neurological complications. In addition, fitting the invasive frame and the need to travel to GammKnife centers often limit access to treatment in this population of elderly patients.

Linear accelerators have greatly improved their precision, now reaching that of GammaKnife. A possible alternative is therefore to treat patients on linear accelerators, without an invasive frame.

The objective of the FRACTHAL study is to assess the feasibility and safety of treatment of essential and / or parkinsonian tremor by fractional radiosurgical thalamotomy on a linear accelerator.

The main hypothesis of the FRACTHAL study is based on the fact that dividing the dose into 3 sessions will both protect healthy tissue around the target while maintaining therapeutic efficacy on the treatment target.

Condition or disease Intervention/treatment Phase
Essential Tremor Parkinsonian Disorders Radiation: Radiosurgical thalamotomy on GammaKnife Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 48 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description:

The study will be carried out according to a design by Simon in two stages (Simon, 1989).

First step: 14 patients will be included in the study. When the 14th patient has been treated, the inclusions will be suspended for 1 year until analysis of the primary endpoint.

• Second stage: 34 additional patients will be recruited for a total of 48 patients.

Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Linac FRACtionated Radiosurgical THALamotomy in Tremors : a Phase II Study
Estimated Study Start Date : March 2021
Estimated Primary Completion Date : March 2026
Estimated Study Completion Date : March 2027

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Radiosurgical thalamotomy on GammaKnife Radiation: Radiosurgical thalamotomy on GammaKnife
fractional radiosurgical thalamotomy on an accelerator (3 sessions of 50 Gy at the isocenter )

Primary Outcome Measures :
  1. Treatment toxicity [ Time Frame: 12 months ]
    The treatment will be considered toxic in the event of the appearance, within 12 months after treatment, of non-regressive toxicity of grade> 1 according to the NCI-CTCAE V5.0 scale (symptomatic neurological deficit interfering with daily activities), and that this deficit is related to the treatment.

Secondary Outcome Measures :
  1. Treatment accuracy [ Time Frame: At 6 and 12 months ]
    Measurement of the shift between the position of the treatment isocenter and the position of the hypersignal center visible on the injected MRI

  2. Tremor improvement [ Time Frame: At 3, 6 and 12 months ]
    It will be measured by decrease in FTM scale score for contralateral upper limb

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • patient with disabling essential tremor, dystonic and / or parkinsonian in one or more limbs superiors ;
  • patient contraindicated or refusing deep brain stimulation ;
  • patient ≥ 18 years old,
  • women of childbearing potential must take effective contraception ;
  • signature of informed consent ; p- atients who benefited from contralateral thalami c stimulation can be included in the study

Exclusion Criteria:

  • brain irradiation history ;
  • contraindication or inability to perform injected MRI ;
  • life expectancy <12 months ;
  • claustrophobic patient who cannot stand the radiotherapy mask ;
  • abnormal anatomy of the thalamic region ;
  • treatment with a trial drug within 30 days of entering the study ;
  • presence of medical, psychological, social or geographic factors likely to modify the patient's compliance with the protocol under study or the monitoring or signing of the consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04727658

Layout table for location contacts
Contact: Cécile ORTHOLAN 00 377 97 98 84 20

Sponsors and Collaborators
Centre Hospitalier Universitaire de Nice
Layout table for additonal information
Responsible Party: Centre Hospitalier Universitaire de Nice Identifier: NCT04727658    
Other Study ID Numbers: 18-01
First Posted: January 27, 2021    Key Record Dates
Last Update Posted: January 27, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: no data sharing is planned

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Essential Tremor
Parkinsonian Disorders
Neurologic Manifestations
Nervous System Diseases
Movement Disorders
Central Nervous System Diseases
Basal Ganglia Diseases
Brain Diseases